In a 32-year-old man with ankylosing spondylitis on naproxen who has persistent morning back pain, limited spinal range of motion, sacroiliac tenderness, and mildly elevated inflammatory markers, should the next step be repeat MRI, initiate methotrexate, initiate sulfasalazine, or refer to physical therapy?

Initiate a TNF Inhibitor (Biologic DMARD)

In this 32-year-old man with active ankylosing spondylitis despite adequate NSAID therapy, the next step should be to initiate a TNF inhibitor (biologic DMARD), not methotrexate, sulfasalazine, or repeat MRI. 1

Why TNF Inhibitor is the Correct Choice

This patient meets the criteria for biologic therapy based on the 2019 ACR/SAA/SPARTAN guidelines 1:

• Active disease despite NSAIDs: He has persistent pain (5/10), limited spinal range of motion, positive sacroiliac provocation tests (FABER maneuver), and mildly elevated inflammatory markers (CRP 2.3, ESR 23)
• Pure axial disease: No peripheral arthritis or synovitis is present on examination
• Strong recommendation: The guidelines provide a strong recommendation (high-quality evidence) for TNF inhibitors in adults with active AS despite NSAID treatment 1

The 2019 guidelines explicitly state: "In adults with active AS despite treatment with NSAIDs, we strongly recommend treatment with TNFi over no treatment with TNFi" 1. This is one of the few strong recommendations in the entire guideline, reflecting robust evidence for efficacy in reducing pain, improving function, and potentially slowing radiographic progression.

Why NOT Methotrexate or Sulfasalazine

Both methotrexate and sulfasalazine are ineffective for pure axial disease in ankylosing spondylitis. This is a critical distinction:

• The 2019 ACR guidelines conditionally recommend these agents only in patients with prominent peripheral arthritis or when TNF inhibitors are not available 1
• The 2006 ASAS/EULAR guidelines explicitly state: "There is no evidence for the efficacy of disease modifying antirheumatic drugs (DMARDs), including sulfasalazine and methotrexate, for the treatment of axial disease" 2
• Systematic reviews confirm no benefit: A Cochrane review found sulfasalazine showed no evidence of benefit in pain, physical function, or spinal mobility for AS 3, and methotrexate showed no statistically significant benefit in examined outcomes 4

This patient has pure axial involvement with no peripheral arthritis, making these conventional DMARDs inappropriate choices.

Why NOT Repeat MRI

A repeat MRI is not indicated at this point:

• The diagnosis is already established (bilateral sacroiliac inflammation on MRI one year ago)
• The 2024 ASAS recommendations state that routine MRI for follow-up is strongly recommended against 5
• The 2019 ACR guidelines note that imaging should not be used routinely for monitoring 1
• Clinical assessment with validated disease activity measures is sufficient for treatment decisions

Why Physical Therapy Alone is Insufficient

While physical therapy is important, it should not be the sole next step:

• The 2019 ACR guidelines strongly recommend physical therapy as an adjunct to pharmacological treatment 1
• However, this patient has already failed adequate NSAID therapy and requires escalation of pharmacological treatment
• Physical therapy should be initiated in combination with TNF inhibitor therapy, not instead of it
• The guidelines emphasize active/supervised exercise over passive modalities 1

Clinical Algorithm for This Patient

Step 1: Confirm adequate NSAID trial

• This patient is on naproxen 500 mg as needed, which may not represent an adequate trial
• The 2006 ASAS guidelines define adequate NSAID trial as: treatment for at least 3 months at maximal recommended or tolerated anti-inflammatory dose 2
• Consider optimizing NSAID therapy first: continuous dosing of naproxen 500 mg twice daily (or another NSAID at full anti-inflammatory dose) for at least 4 weeks

Step 2: If symptoms persist despite optimized NSAIDs (as appears to be the case here)

• Initiate TNF inhibitor therapy
• No preference for specific TNF inhibitor (all are equally effective) 1
• Options include: adalimumab, etanercept, infliximab, golimumab, certolizumab

Step 3: Concurrent interventions

• Strongly recommend referral to physical therapy for supervised exercise program 1
• Active exercises focusing on spinal mobility and posture
• Land-based over aquatic therapy 1

Step 4: Monitoring

• Use validated disease activity measures (BASDAI, ASDAS) at regular intervals 1
• Assess for extramusculoskeletal manifestations (uveitis, IBD, psoriasis) that might influence biologic choice

Important Caveats

Before initiating TNF inhibitor:

• Screen for latent tuberculosis (required)
• Screen for hepatitis B and C
• Update vaccinations (avoid live vaccines after starting therapy)
• Counsel about infection risk

If TNF inhibitors are not accessible due to insurance or cost:

• Then and only then consider sulfasalazine or methotrexate as a conditional recommendation 1
• However, set appropriate expectations about limited efficacy for axial symptoms

Alternative biologics: IL-17 inhibitors (secukinumab, ixekizumab) are also strongly recommended for active AS despite NSAIDs 1, though TNF inhibitors are conditionally preferred as first-line biologic therapy 1